[go: up one dir, main page]

WO2009066655A1 - アポトーシス誘導能を有するヒト抗体 - Google Patents

アポトーシス誘導能を有するヒト抗体 Download PDF

Info

Publication number
WO2009066655A1
WO2009066655A1 PCT/JP2008/070929 JP2008070929W WO2009066655A1 WO 2009066655 A1 WO2009066655 A1 WO 2009066655A1 JP 2008070929 W JP2008070929 W JP 2008070929W WO 2009066655 A1 WO2009066655 A1 WO 2009066655A1
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
fragment
human antibody
antibody capable
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/070929
Other languages
English (en)
French (fr)
Inventor
Yuji Ito
Masanori Baba
Naomichi Arima
Yasuo Suda
Toshihiro Nakashima
Masaharu Torikai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemo Sero Therapeutic Research Institute Kaketsuken
Kagoshima University NUC
Original Assignee
Chemo Sero Therapeutic Research Institute Kaketsuken
Kagoshima University NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemo Sero Therapeutic Research Institute Kaketsuken, Kagoshima University NUC filed Critical Chemo Sero Therapeutic Research Institute Kaketsuken
Priority to US12/743,739 priority Critical patent/US20110117602A1/en
Priority to JP2009542551A priority patent/JPWO2009066655A1/ja
Publication of WO2009066655A1 publication Critical patent/WO2009066655A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • G01N33/5758—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

　ATL細胞をはじめとした複数の腫瘍細胞株に対して特異的な反応性を有し、かつ安全性と治療効果を兼ね備えたヒト抗体及び該抗体フラグメントを提供する。腫瘍細胞の表面に発現するHLA-DRβ鎖を認識するヒト抗体及び該抗体フラグメントを得た。特に該抗体フラグメントであるscFvの二量体（ダイアボディ）が該HLA-DRβ鎖発現細胞に対する強いアポトーシス誘導能を有することを見出した。本発明により得られた抗体及び該抗体フラグメントは、ATLをはじめとした癌及び／またはウイルス感染症の検出試薬、診断薬および予防または治療薬として有用である。
PCT/JP2008/070929 2007-11-19 2008-11-18 アポトーシス誘導能を有するヒト抗体 Ceased WO2009066655A1 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US12/743,739 US20110117602A1 (en) 2007-11-19 2008-11-18 Human antibody capable of inducing apoptosis
JP2009542551A JPWO2009066655A1 (ja) 2007-11-19 2008-11-18 アポトーシス誘導能を有するヒト抗体

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007299551 2007-11-19
JP2007-299551 2007-11-19

Publications (1)

Publication Number Publication Date
WO2009066655A1 true WO2009066655A1 (ja) 2009-05-28

Family

ID=40667477

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/070929 Ceased WO2009066655A1 (ja) 2007-11-19 2008-11-18 アポトーシス誘導能を有するヒト抗体

Country Status (3)

Country Link
US (1) US20110117602A1 (ja)
JP (1) JPWO2009066655A1 (ja)
WO (1) WO2009066655A1 (ja)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012046745A1 (ja) * 2010-10-04 2012-04-12 独立行政法人理化学研究所 Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬
EP2591002A2 (en) * 2010-07-07 2013-05-15 Tubitak Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2 /kdr)
WO2020171171A1 (ja) * 2019-02-22 2020-08-27 ブライトパス・バイオ株式会社 抗ｈｌａ－ｄｒ抗体、およびそのがん治療用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033538A1 (en) * 2001-10-15 2003-04-24 Kirin Beer Kabushiki Kaisha Anti-hla-dr antibody
WO2004033499A1 (ja) * 2002-10-11 2004-04-22 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
WO2006094192A2 (en) * 2005-03-03 2006-09-08 Immunomedics, Inc. Humanized l243 antibodies

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003033538A1 (en) * 2001-10-15 2003-04-24 Kirin Beer Kabushiki Kaisha Anti-hla-dr antibody
WO2004033499A1 (ja) * 2002-10-11 2004-04-22 Chugai Seiyaku Kabushiki Kaisha 細胞死誘導剤
WO2006094192A2 (en) * 2005-03-03 2006-09-08 Immunomedics, Inc. Humanized l243 antibodies

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
KOSTELNY SA ET AL.: "Humanization and characterization of the anti-HLA-DR antibody 1D10.", INT J CANCER., vol. 93, no. 4, 2001, pages 556 - 565 *
NAGY ZA ET AL.: "Fully human, HLA-DR-specific monoclonal antibodies efficiently induce programmed death of malignant lymphoid cells.", NAT MED., vol. 8, no. 8, 2002, pages 801 - 807 *
TAWARA T ET AL.: "Fully human antibody exhibits pan-human leukocyte antigen-DR recognition and high in vitro/vivo efficacy against human leukocyte antigen-DR-positive lymphomas.", CANCER SCI., vol. 98, no. 6, June 2007 (2007-06-01), pages 921 - 928 *
WAKAMATSU S ET AL.: "Monocyte-driven activation-induced apoptotic cell death of human T-lymphotropic virus type I-infected T cells.", J IMMUNOL., vol. 163, no. 7, 1999, pages 3914 - 3919 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2591002A2 (en) * 2010-07-07 2013-05-15 Tubitak Recombinant antibody structures binding to and blocking the activity of vascular endothelial growth factor 2 (vegfr- 2 /kdr)
JP2013540420A (ja) * 2010-07-07 2013-11-07 テュビタク−テュルキイェ・ビリムセル・ヴェ・テクノロジク・アラスティルマ・クムル 血管内皮増殖因子２（ｖｅｇｆｒ−２／ｋｄｒ）に結合し、その活性を遮断する組換え抗体構造
WO2012046745A1 (ja) * 2010-10-04 2012-04-12 独立行政法人理化学研究所 Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬
JP5884139B2 (ja) * 2010-10-04 2016-03-15 国立研究開発法人理化学研究所 Ｍｈｃクラスｉｉを発現する悪性腫瘍の治療薬
US9303083B2 (en) 2010-10-04 2016-04-05 Riken Therapeutic agent for malignant tumors expressing MHC class II
WO2020171171A1 (ja) * 2019-02-22 2020-08-27 ブライトパス・バイオ株式会社 抗ｈｌａ－ｄｒ抗体、およびそのがん治療用途

Also Published As

Publication number Publication date
US20110117602A1 (en) 2011-05-19
JPWO2009066655A1 (ja) 2011-04-07

Similar Documents

Publication Publication Date Title
WO2012082494A3 (en) The use of anti-cxcl13 and anti-cxcr5 antibodies for the treatment or detection of cancer
WO2011041584A3 (en) Methods for modulation of autophagy through the modulation of autophagy-enhancing gene products
WO2012170776A3 (en) Methods of determining a patient's prognosis for recurrence of prostate cancer and/or determining a course of treatment for prostate cancer following a radical prostatectomy
WO2012045001A3 (en) Influenza virus antibodies and immunogens and uses therefor
NZ729158A (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
WO2011045080A3 (en) Monoclonal antibodies to progastrin and their uses
WO2011139974A3 (en) Anti-pai-1 antibodies and methods of use thereof
WO2011151252A3 (en) Means and methods for diagnosing pancreatic cancer in a subject
WO2012071561A3 (en) Anti-il-6 antibodies for the treatment of anemia
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
WO2016154003A8 (en) Neutralizing antibodies to gp120 and their use
WO2009079587A3 (en) Biomarkers for sensitivity to anti-igf1r therapy
WO2013142324A8 (en) Neutralizing antibodies to hiv-1 and their use
WO2011143624A3 (en) Humanized and chimeric monoclonal antibodies to cd47
HK1213924A1 (zh) 用於治療癌症的抗kir和抗ctla-4抗體組合
WO2007109376A3 (en) Anti-tumor cell antigen antibody therapeutics
WO2013025882A3 (en) Tricyclic compounds as anticancer agents
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
NZ616382A (en) Antibodies specific to cadherin-17
WO2012021887A3 (en) Biomarkers for the early detection of breast cancer
WO2007135546A3 (en) TREATMENT OF CANCER WITH ANTI-IL-1α ANTIBODIES
WO2010009879A3 (en) Methods for producing paricalcitol
WO2011035205A3 (en) Antibodies against candida, collections thereof and methods of use
WO2008066784A3 (en) Expression of foxp3 by cancer cells
WO2009114560A3 (en) Compositions and methods for the therapy and diagnosis of cytomegalovirus infections

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08851216

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2009542551

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 12743739

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 08851216

Country of ref document: EP

Kind code of ref document: A1